1. Umemura et al., Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study
60 patient nintedanib late treatment study: 14% lower mortality (p=1) and 34% improvement (p=0.03).Analysis of 60 mechanically ventilated COVID-19 patients (30 nintedanib, 30 historical controls) showing no significant difference in 28-day mortality or the need for mechanical ventilation, but shorter mechanical ventilation duration (p=0.046) and lower CT high-attenuation areas after mechanical ventilation. Major limitations include the non-randomized historical control design and small size.
Jul 2021, Int. J. Infectious Diseases, https://www.sciencedirect.com/science/article/pii/S1201971221004562, https://c19p.org/umemura